Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

In patients with active lymphocytic myocarditis and persistent heart failure for greater than 6 months, those with circulating cardiac autoantibodies and no viral genomes detected on myocardial biopsy are the most likely to benefit from immunosuppressive therapy.

Immunosuppressive Therapy for Myocarditis